Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Cencora, Inc.
McKesson Corporation
Merit Medical Systems Inc
AMN Healthcare Services
Hologic Inc
Elevance Health, Inc.
Integer Holdings Corporation
Haemonetics Corporation
DexCom, Inc.
The chart shows the growth of an initial investment of $10,000 in Cardinal Health, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Cardinal Health, Inc. (CAH) has returned 4.63% so far this year and 70.72% over the past 12 months. Looking at the last ten years, CAH has achieved an annualized return of 10.03%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Cardinal Health, Inc. (CAH) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.04% | 6.20% | -8.93% | 1.27% | ||||||||
| 2025 | 4.54% | 4.49% | 6.52% | 2.71% | 10.31% | 8.94% | -7.36% | -3.83% | 6.15% | 22.44% | 11.09% | -3.47% |
| 2024 | 8.45% | 7.67% | -2.23% | -7.75% | -2.91% | -0.25% | 2.71% | 11.28% | -2.20% | -1.76% | 8.30% | -3.77% |
| 2023 | 1.03% | -1.68% | 0.07% | 8.33% | 0.15% | 14.16% | -2.52% | -4.36% | -0.90% | 5.84% | 17.58% | -5.80% |
| 2022 | 0.10% | 5.06% | 5.00% | 2.31% | -4.19% | -7.83% | 13.49% | 18.88% | -5.31% | 13.64% | 5.50% | -4.27% |
| 2021 | -0.28% | -4.47% | 16.96% | -0.40% | -7.93% | 1.77% | 3.92% | -11.68% | -5.61% | -3.76% | -3.10% | 9.76% |
| 2020 | 0.57% | 1.34% | -8.35% | 7.22% | 11.61% | -4.20% | 4.40% | -8.62% | -7.07% | -2.97% | 16.65% | -3.32% |
| 2019 | 13.26% | 10.51% | -11.91% | 0.08% | -13.61% | 11.93% | -3.58% | -7.25% | 10.36% | 4.08% | 10.61% | -8.09% |
| 2018 | 16.35% | -1.98% | -9.51% | 1.45% | -18.19% | -7.90% | 2.15% | 4.46% | 3.85% | -6.49% | 8.36% | -18.91% |
| 2017 | 4.13% | 9.32% | -0.77% | -11.18% | 3.92% | 4.99% | -1.06% | -13.20% | -1.14% | -7.91% | -2.66% | 3.94% |
| 2016 | -3.94% | 1.87% | -0.73% | 7.29% | -4.25% | -2.75% | -11.25% | 3.62% | 1.45% |
The charts below present risk-adjusted performance metrics for Cardinal Health, Inc. (CAH) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CAH compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Cardinal Health, Inc. volatility is 1.48%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 53.12B | 45.12B | 43.42B | 43.88B | 44.45B | 40.77B | 40.96B | 39.95B | 40.11B | 34.12B | 30.14B | 26.03B | 25.82B | 24.26B | 22.85B |
| Temporary Equity (USD) | - | - | - | - | - | - | - | 12.00M | 118.00M | 117.00M | - | - | - | - | - |
| Equity Attributable To Parent (USD) | -2.78B | -3.21B | -2.85B | -709.00M | 1.79B | 1.79B | 6.33B | 6.06B | 6.81B | 6.55B | 6.26B | 6.40B | 5.98B | 6.24B | 5.85B |
| Equity Attributable To Noncontrolling Interest (USD) | 147.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.00M | - | 20.00M | 17.00M | - | - | - | - | - |
| Equity (USD) | -2.63B | -3.21B | -2.85B | -706.00M | 1.79B | 1.79B | 6.33B | 6.06B | 6.83B | 6.57B | 6.26B | 6.40B | 5.98B | 6.24B | 5.85B |
| Redeemable Noncontrolling Interest (USD) | - | - | - | - | - | - | - | 12.00M | 118.00M | 117.00M | - | - | - | - | - |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.13B |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.50B |
| Noncurrent Liabilities (USD) | 16.86B | 12.69B | 12.56B | 14.03B | 15.04B | 15.36B | 10.52B | 11.00B | 12.06B | 7.85B | 6.64B | 4.52B | 5.25B | 3.84B | 3.63B |
| Other Current Liabilities (USD) | 4.18B | 3.88B | 3.89B | 3.42B | 3.92B | 2.24B | 2.57B | 3.22B | 3.32B | 2.40B | 2.88B | 2.97B | 2.30B | 2.45B | 2.04B |
| Accounts Payable (USD) | 34.71B | 31.76B | 29.81B | 27.13B | 23.70B | 21.37B | 21.54B | 19.68B | 17.91B | 17.31B | 14.37B | 12.15B | 12.30B | 11.73B | 11.33B |
| Current Liabilities (USD) | 38.90B | 35.64B | 33.71B | 30.55B | 27.62B | 23.62B | 24.11B | 22.89B | 21.22B | 19.70B | 17.24B | 15.12B | 14.59B | 14.17B | 13.37B |
| Liabilities (USD) | 55.76B | 48.33B | 46.27B | 44.58B | 42.66B | 38.97B | 34.63B | 33.89B | 33.28B | 27.55B | 23.89B | 19.63B | 19.84B | 18.02B | 17.00B |
| Other Non-current Assets (USD) | 11.41B | 5.98B | 5.65B | 6.81B | 8.94B | 9.54B | 9.43B | 9.00B | 7.90B | 8.11B | 5.94B | 5.64B | 5.59B | 4.79B | 4.60B |
| Intangible Assets (USD) | 2.49B | 1.73B | 1.47B | 1.77B | 2.11B | 2.92B | 3.43B | 3.91B | 1.99B | 2.26B | 948.00M | 992.00M | 973.00M | 414.00M | 413.40M |
| Fixed Assets (USD) | 2.86B | 2.53B | 2.46B | 2.36B | 2.36B | 2.37B | 2.36B | 2.49B | 1.88B | 1.80B | 1.51B | 1.46B | 1.49B | 1.55B | 1.51B |
| Noncurrent Assets (USD) | 16.75B | 10.24B | 9.58B | 10.94B | 13.41B | 14.83B | 15.22B | 15.40B | 11.77B | 12.17B | 8.39B | 8.09B | 8.05B | 6.75B | 6.53B |
| Other Current Assets (USD) | 6.30B | 7.84B | 6.55B | 6.74B | 7.35B | 4.48B | 4.48B | 4.45B | 9.00B | 3.94B | 6.02B | 4.29B | 3.09B | 3.29B | 2.83B |
| Inventory (USD) | 16.83B | 14.96B | 15.94B | 15.64B | 14.59B | 13.20B | 12.82B | 12.31B | 11.30B | 10.62B | 9.21B | 8.27B | 8.37B | 7.86B | 7.33B |
| Accounts Receivable (USD) | 13.24B | 12.08B | 11.34B | 10.56B | 9.10B | 8.26B | 8.45B | 7.80B | 8.05B | 7.41B | 6.52B | 5.38B | 6.30B | 6.36B | 6.16B |
| Current Assets (USD) | 36.37B | 34.88B | 33.83B | 32.94B | 31.05B | 25.94B | 25.75B | 24.55B | 28.35B | 21.96B | 21.75B | 17.94B | 17.77B | 17.51B | 16.32B |
| Assets (USD) | 53.12B | 45.12B | 43.42B | 43.88B | 44.45B | 40.77B | 40.96B | 39.95B | 40.11B | 34.12B | 30.14B | 26.03B | 25.82B | 24.26B | 22.85B |
The article examines three high-ROIC dividend-paying stocks: MasterCard, which reported strong Q4 2025 earnings with 17.3% revenue growth and 19% annual EPS growth; Starbucks, showing accelerating comparable store sales growth to 4% with expansion opportunities in China; and Cardinal Health, a major drug distributor posting 18.6% revenue growth and 39 consecutive years of dividend increases.
The global medical device cleaning market is projected to grow from USD 2.08 billion in 2024 to USD 3.74 billion by 2032, driven by escalating infection prevention requirements, expanding reusable device utilization, and technological advancements in automated reprocessing systems. However, high capital costs, complex regulatory obligations, and workforce training variability pose challenges to uniform adoption across regions.
Cardinal Health's Board of Directors approved a quarterly dividend of $0.5107 per share, payable on April 15, 2026 to shareholders of record as of April 1, 2026. The dividend will be paid from the company's capital surplus.
Cardinal Health (CAH) surged 9.11% to a new 52-week high after reporting strong Q2 results with adjusted EPS of $2.63 (beating consensus of $2.35) and sales of $65.63 billion (+19% YoY). The company raised its fiscal 2026 guidance for adjusted EPS to $10.15-$10.35 (+23% to +26% growth) and raised profit growth guidance across multiple segments.
Medline Industries, the largest IPO of 2025, is positioned as an attractive investment opportunity. The Chicago-based medical supply company has demonstrated strong historical growth with 18% average annual sales growth since 1966 and 50 consecutive years of net sales growth. With a $375 billion total addressable market and solid free cash flow projections, analysts expect continued momentum, though the stock trades at a lofty P/E multiple of 28.
A comprehensive market report on the U.S. Personal Protective Equipment market covering gowns, masks, face shields, gloves and other segments through 2033. The report provides revenue, volume, and pricing data across market segments with company share information for 2024, identifying key opportunities for market entry, expansion, and investment strategies.
AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.
The global pharmaceutical waste management market is projected to grow at a CAGR of 5.91% from 2026 to 2032, reaching USD 2631.59 million by 2032, up from USD 1662.35 million in 2024. Growth is driven by stringent regulatory frameworks, expanding pharmaceutical industry, and rising sustainability focus, though high operational costs and fragmented regulations present challenges.
The global adhesive bandages market is expected to grow to $4.48 billion by 2032, driven by rising minor injuries, increased healthcare awareness, and product innovations, despite challenges like skin irritation and pricing pressures.
The article highlights three dividend stocks with strong potential: Cardinal Health, Chevron, and Target. Each company offers unique dividend growth opportunities based on their financial performance, transformation strategies, and commitment to shareholder returns.